|
Apr 4
|
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
|
|
Apr 4
|
How Adverum (ADVM) Stock Stands Out in a Strong Industry
|
|
Apr 3
|
Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround
|
|
Mar 27
|
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
|
|
Mar 20
|
Adverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial Adjustments
|
|
Mar 19
|
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
|
|
Mar 18
|
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
|
|
Feb 8
|
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
|
|
Feb 5
|
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
|
|
Jan 29
|
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
|
|
Jan 4
|
Here's Why You Should Invest in Adverum (ADVM) Stock Now
|
|
Dec 7
|
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
|
|
Nov 28
|
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
|
|
Aug 10
|
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
|